In early 2022, the AACU joined more than 20 other organizations in supporting biomarker testing legislation introduced in Ohio (HB 608). This legislation continues to move forward, and passed the House Health Committee this week with only one vote in opposition. Bills like this are on AACU’s radar because they would ensure that Ohioans covered by state-regulated insurance plans, including Medicaid, have coverage for biomarker testing when medically appropriate. Improving access to biomarker testing and thereby access to targeted therapies is also an important strategy to reduce health disparities and improve outcomes for cancer patients. 

The AACU submitted written testimony on behalf of urologists and patients in Ohio, and we will continue to update our members as this progresses through the legislature.